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OBJECTIVES: Histopathology is the ‘gold standard’ for diagnosing renal cell carcinoma but is limited by sample
size. Contrast-enhanced ultrasound can differentiate malignant and benign lesions, but the Chinese guidelines
on the management of renal cell carcinoma do not include this method. The purpose of this study was to
compare the diagnostic parameters of contrast-enhanced ultrasound against those of contrast-enhanced
computed tomography for detecting kidney lesions, with histopathology considered the reference standard.
METHODS: Patients with suspected kidney lesions from prior grayscale ultrasonography and computed
tomography were included in the analysis (n=191). The contrast-enhanced ultrasound, contrast-enhanced
computed tomography, and histopathology data were collected and analyzed. A solid, enhanced mass was
considered a malignant lesion, and an unenhanced mass or cyst was considered a benign lesion. The Bosniak
criteria were used to characterize the lesions.
RESULTS: Contrast-enhanced ultrasound and contrast-enhanced computed tomography both detected that
151 patients had malignant tumors and 40 patients had benign tumors. No significant differences in the tumors
and their subtypes were reported between contrast-enhanced ultrasound and histopathology (p=0.804).
Chromophobe renal cell carcinoma was detected through contrast-enhanced computed tomography (n=1), but
no such finding was reported by contrast-enhanced ultrasound. A total of 35 cases of papillary renal cell
carcinoma were reported through contrast-enhanced ultrasound while 32 were reported through histopathology.
CONCLUSIONS: Contrast-enhanced ultrasound might be safe and as accurate as histopathology in diagnosing
kidney lesions, especially renal cell carcinoma. Additionally, this study provides additional information over
histopathology and has an excellent safety profile.
Level of evidence: III.
KEYWORDS: Chromophobe Renal Cell Carcinoma; Contrast-Enhanced Computed Tomography; Contrast-
Enhanced Ultrasound; Histopathology; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma.
’ INTRODUCTION
Lesions are characterized by their location in the body,
size, and cause. Lesions can occur anywhere in the body, but
lesions usually develop in the soft tissues i.e. the brain, skin,
kidney, and lung. Renal lesions can be benign or malignant.
To differentiate these lesions, various techniques are used,
e.g., histopathology, ultrasound, computed tomography (CT)
scans, and magnetic resonance imaging (MRI). The features
that distinguish benign lesion from malignant lesions are
their size and growth pattern (1).
There are two distinctive growth patterns of kidney lesions,
ball and bean. The most common renal solid masses are ball-
shaped, usually renal cell carcinoma (RCC), which deform
the bean-shaped contour part of the kidney. The bean-type
growth pattern retains the renal shape of the kidney and
infiltrates into the renal parenchyma (Figure 1). Ball-type
lesions can be easily detected, but it is difficult to detect bean-
type renal masses using conventionally available techniques
(2). A large tumor size is considered a hallmark feature
of malignancy. It is of utmost importance to characterize the
size of the tumor using imaging method(s) and/or histo-
pathology (3).
RCC is most common kidney lesion and is associated with
the age of the patients. Usually, RCC is reported in adults
aged 60 years or older. There are various subtypes of RCCDOI: 10.6061/clinics/2020/e1489
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classified by the World Health Organization (WHO). The
most commonly observed RCC is clear cell carcinoma, and
70% of RCC cases are clear cell carcinoma. This carcinoma
is heterogeneous and extensive. Chromophobe (5% of the
cases) and papillary RCC (10–15% of the cases) are also quite
common. Smaller papillary RCC is hypovascular and homo-
genous. Smaller papillary RCC usually presents as micro-
cysts. In contrast, chromophobe RCCmanifests as sharp lesions
with lobes. The least frequently observed types are renal
medullary RCC and multilocular cystic RCC (Figure 2) (4).
The most frequently observed renal lesion that is not RCC
is angiomyolipoma. It contains fat and smooth muscles. The
second most commonly observed benign renal lesion that
is not RCC is oncocytoma. It is essential to differentiate
and identify various types of renal lesions to provide proper
treatment to the patient (2).
Ultrasound waves are sound waves with frequencies
above 20,000 Hz. The application of contrast medium to con-
ventional ultrasound is a common technique used in medical
science. For sonographic examinations, the contrast agents
generally used are microbubbles with a size of 10-12 mm.
These microbubbles are made of saline, perfluorocarbons, or
nitrogen and are supported with the help of polymer shells,
lipids, or proteins. Gas-filled contrast media are commer-
cially available and are administered intravenously. High
contrast can be observed with the use of these agents due to
the differential reflection of ultrasound waves from interfaces
existing between different substances (5).
Contrast-enhanced ultrasound (CEUS) is an advanced
technique and has various advantages over conventional
techniques like traditional unenhanced ultrasound, MRI, or
histopathology. CEUS is able to differentiate between renal
solid masses, renal lesions, small cysts, complex cysts, and
pseudolesions. This is why CEUS has become a potential tool
for observing and characterizing renal lesions (6).
CEUS is a relatively advanced and is an emerging techno-
logy. It is able to depict the kidney physiology and anatomy.
Contrast agents were introduced in 1996 for ultrasonography
and are still being used, and new agents are emerging. CEUS
causes no nephrotoxicity or radiation hazards and does not
cause discomfort to the patient (7).
Histopathology is considered as the ‘gold standard’ in
various clinical diagnostic processes in research laboratories.
It is used as a benchmark to confirm results obtained through
various advanced processes. However, histopathology is a
laborious task that can take anywhere from hours to days
and certainly depends on the expertise of the histopathologists.
This is why sometimes artifacts due to toned tissue sections
or inconsistent staining appear. Histopathology is also limited
by the sample size that can be analyzed, and only a small area
of interest can be observed. On the other hand, there are
techniques like CEUS that allow observation of the whole
organ (8).
CEUS has the ability to differentiate between benign and
malignant tumors and can determine the degree of malig-
nancy, especially for focal liver lesions, as suggested by
various studies (9). The guidelines and recommendations for
the use of CEUS in clinical practices have put great emphasis
on extrahepatic applications (10). Diverse applications of
CEUS in modern medicine have been discussed in this
document. No single radiologist is able to master all of these
applications, but individually, these evaluations have the
potential to replace CT and MRI (11). The guidelines also
recommend the use of CEUS in the diagnosis of kidney lesions
and observation of the pancreas and urinary tract (12).
CEUS can serve as a useful tool for the differentiation
between pseudotumors and neoplasms. For example, CEUS
can distinguish between dromedary hump and column of
Bertin in the kidney (extensions of the renal cortical tissue that
are involved in separating nephrons). These features are
normal in 50% of the population (13). However, dromedary
hump can also mimic renal neoplasms. These structures are
Figure 1 - Pictorial presentation of renal lesions. Ball-type and bean-type renal lesions.
Figure 2 - Frequency of occurrence of different types of renal cell
carcinoma in the population.
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the budges on the lateral border of the kidney and are benign
lesions (14).
If there is a similarity between the enhancement pattern
and adjacent renal parenchyma, then the mass under study is
a pseudotumor and not a neoplasm. CEUS can detect lesions
that are not detectable by grayscale ultrasound (9). The
distinction between malignant renal tumors and benign
lesions is necessary because of the high prevalence of kidney
cancer in the Chinese population (15). If the lesion is identi-
fied in an earlier stage, then treatment is possible. Therefore,
it is necessary to differentiate between malignant and benign
lesions, and CEUS can accomplish this task. Benign renal
lesions are very common, and 30% of the reported lesions
were benign (16).
The objectives of this retrospective study were to evaluate
the efficiency of CEUS in differentiating between benign and
malignant tumors, identifying the lesion subtypes, and
determining the malignant nature and to assess the accuracy
and sensitivity of CEUS in comparison to those of contrast-
enhanced computed tomography (CECT), considering histo-
pathology as the ‘reference standard’.
’ MATERIALS AND METHODS
Ethics approval and consent to participate
The designed study protocol (SPL/CL/17/19 dated 21
May 2019) was approved by the Second People’s Hospital of
Lanzhou Review Board. Informed consent forms were signed
by the enrolled patients for pathology, radiology, anesthesia,
and publication of the study in all formats of the publication
house, including the publication of personal data and images
during hospitalization, irrespective of time and language. The
study reporting adhered to the laws of China, the Strengthen-
ing the Reporting of Observational Studies in Epidemiology
(STROBE): Cross-sectional Studies statement, and the v2008
Helsinki Declaration.
Inclusive criteria
Patients aged above 18 years with elevated serum creati-
nine who had undergone prior imaging (grayscale ultra-
sonography and CT) as a part of routine clinical care to
evaluate kidney structure and size and had suspected kidney
lesions were included in the analysis.
Exclusion criteria
Individuals with active cardiac disease (unstable angina,
myocardial infarction, and severe arrhythmia), lung cancer,
respiratory distress syndrome, emphysema, hypersensitivity
response against contrast agents, especially Levovists (a mix-
ture of galactose microparticles, air bubbles, and palmitic
acid) and iohexol, were excluded from radiology. Patients
who had a history of drug abuse were also excluded from
radiology. Pregnant women and breastfeeding females were
also excluded from radiology. Individuals in critical condi-
tion or intensive care unit status and those who declined to
undergo radiological and/or pathological examinations were
excluded.
Data collection
Patients who gave consent for diagnostic procedures
during hospitalization filled out a consent form and pro-
vided general information about their lifestyle. The grayscale
ultrasonography, CT, CEUS, CECT, and histopathology data
were collected.
Untargeted contrast-enhanced ultrasound
The patients were instructed to lay down on a bed, and a
2.5 g bolus Levovists (Schering AG, Berlin, Germany) was
administered intravenously. When the microbubbles passed
through the imaging system, the signal oscillated and reflec-
ted, and the ultrasound images were recorded by a Sonoline
Elegra medical ultrasound system (K981528, Siemens Health-
care, Hamburg, Germany) using 4 MHz abdominal transdu-
cers (Siemens Healthcare, Hamburg, Germany). The arterial
phase ultrasound image was recorded at a 2.8 MHz frequency,
100% maximum output with a single point focus, and a 5/s
frame rate, which was decreased to 2/s and eventually to 1/s.
The echogenicity was converted into a high-contrast image of
the area of interest (17). Sonographers (minimum 5 years of
experience) acquired the scans.
Contrast-enhanced computed tomography
The patients were instructed to lay down on a bed, 100 mL
iohexol (755 mg/mL, Omnipaquet, GE Healthcare, Chicago,
IL, USA) was administered intravenously at 4 mL/s, and the
images were recorded by a 16-slice CT scanner (GE Health-
care, Chicago, IL, USA) (18). Radiologists (minimum 5 years
of experience) acquired the scans.
Image analysis
Grayscale ultrasound, CT, CEUS, and CECT images were
uploaded on a RadiAnt DICOM Viewer-Chinese system
(Medixant Maciej Frankiewicz, Poznan, Poland), and the
Bosniak criteria were used to characterize the lesions (18).
A solid, enhanced mass was considered a malignant lesion,
and an unenhanced mass or cyst was considered a benign
lesion (19). Sonographers and radiologists (minimum of
5 years of experience) were involved in the image analysis.
Histopathology
With a 20G, 20 cm semiautomatic biopsy gun (Supercore,
Varay Laborix, Bourges, France), the tissues were collected
by physicians (minimum 5 years of experience). After dis-
section, the tissues were placed in a fixative buffer (Carnoy’s
solution, Mark Specialist, Berlin, Germany) to prevent decay.
The part of the tissue that was expected to bring about
accurate manifestations of the disease was removed (2-3 mm)
and placed on the slide using formalin (Mark Specialist,
Berlin, Germany) as a fixative. Moisture was removed from
the samples using varying concentrations of ethanol (Mark
Specialist, Berlin, Germany) and xylene (Mark Specialist,
Berlin, Germany). Wax (Mark Specialist, Berlin, Germany)
was introduced at the end to adhere the tissue sample on the
slide. The slide was stained with hematoxylin (Mark Specia-
list, Berlin, Germany) and eosin (Mark Specialist, Berlin,
Germany) to enable microscopic observation. After observa-
tion, digital cameras captured advanced images of the histo-
pathological specimen (2).
The histopathology of the renal lesions was characterized
on the basis of different patterns of staining and observable
appearances of the slides (20) (Table 1). Pathologists (mini-
mum 5 years of experience) were involved in the histo-
pathological analysis.
Statistical analysis
The correlation of the CEUS, CECT, and histological results
was analyzed based on the expert evaluations of the type
and subtype of lesions. The chi-square independence test (2)
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was performed for constant data. The results were consid-
ered significant at the 95% confidence level.
’ RESULTS
Enrollment
From 15 January 2017 to 31 December 2018, patients enrol-
led at the Second People’s Hospital of Lanzhou, Lanzhou,
China and the First People’s Hospital of Tian Shui GanSu
Province, Tianshui, China underwent imaging examinations
as a part of routine clinical care to evaluate kidney structure
and size. Grayscale ultrasound (Figure 3) and CT (Figure 4)
images suggested kidney lesions in 241 patients with ele-
vated serum creatinine levels during routine clinical care. Of
these patients, seven were excluded due to very high blood
pressure, two were excluded because of congenital heart
disorders, two women were breastfeeding and could not
undergo CEUS/CECT, and 39 patients declined to undergo
radiological examinations. The grayscale ultrasound, CT,
CECU, CECT, and histopathology data of 191 patients were
included in the analysis. A flow diagram of the study is
presented in Figure 5.
Demographic and clinical characteristics
Out of 191 patients, 137 (72%) were men, and 54 (28%)
were women. The mean age of the enrolled patients was
63.51±12.25 years, 120 patients were smokers (15 cigars per
day), and 71 had never smoked any kind of tobacco product.
The other demographic and clinical characteristics of the
enrolled patients are reported in Table 2.
Untargeted contrast-enhanced ultrasound
CEUS showed tumor blood flow in all of the patients.
CEUS detected 151 patients with malignant tumors and
40 patients with benign tumors. A total of 104 individuals had
clear cell carcinoma, 35 had papillary RCC (papillary RCC-
type I and papillary RCC-type II), six individuals had collec-
ting duct carcinoma, six patients had infiltrative urothelial
carcinoma, 27 individuals had angiomyolipoma, and 13
patients were diagnosed with oncocytomas, according to
CEUS (Figure 6).
Contrast-enhanced computed tomography
Contrast-enhanced computed tomography detected 151
patients with malignant tumors and 40 patients with benign
tumors. A total of 104 individuals had clear cell RCC,
35 patients had papillary RCC (papillary RCC-type I and
papillary RCC-type II), six individuals had collecting duct
carcinoma, six had infiltrative urothelial carcinoma, 27 indi-
viduals had angiomyolipoma, 12 were diagnosed with
oncocytomas, and one individual had chromophobe RCC
(Figure 7).
Histopathology
The results of CEUS and CECT for renal lesions had some
contradictions, and these contradictions were clarified using
Table 1 - Interpretation of the histopathological examinations.
Observations Interpretation
Lipid-rich cytoplasm with sharply visible
nuclei
Clear cell renal cell
carcinoma
Spindle-shaped basophilic cells with scarce
cytoplasm
Papillary renal cell
carcinoma type I
Spindle-shaped organized cells covered with
granular eosinophils with distinct visible
nuclei
Papillary renal cell
carcinoma type II
Irregular channels lined by high grade
cuboidal to hobnail cells with eosinophilic
cytoplasm
Collecting duct renal cell
carcinoma
Sessile, polypoid, fungating, ulcerated, and
infiltrative lesion with the neoplastic cells
separated by a desmoplastic stroma
Infiltrative urothelial
renal cell carcinoma
Hemorrhagic cysts with a line of epithelial
cells and clear cytoplasm
Medullary cystic renal
cell carcinoma
Varying amounts of smooth muscle cells
(appear to originate and ‘‘radiate’’ off the
vessels), mature fat and thick-walled
abnormal vessels
Angiomyolipoma
Nested architecture with a central scar and
bland cytology
Oncocytomas
Large cells with pale surroundings and
perinuclear halos
Chromophobe renal cell
carcinoma
Figure 3 - Grayscale ultrasonography showing a suspected mass-
mimicking lesion in the right kidney in a 53-year-old man with
clear cell renal carcinoma.
Figure 4 - Computed tomography showing a suspected mass-
mimicking lesion in the right kidney in a 55-year-old man with
clear cell renal carcinoma.
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histopathology. The histopathology results showed that out
of 191 patients, 148 had malignant lesions, and 43 had benign
lesions. Forty-three individuals had histopathology results
indicative of benign tumors and suggestive of angiomyoli-
poma (n=30) and oncocytomas (n=12) (Figure 8).
Diagnostic parameters
No significant differences between CEUS and histopathol-
ogy (p = 0.804) or between CECT and histopathology
(p=0.804) were reported for tumors and their subtypes.
Histopathology suggested that the results of CEUS were
more accurate for diagnosing kidney lesions. CEUS had a
sensitivity of 0.99, and CECT had a sensitivity of 1 compared
to histopathology. The specificities of the diagnostic methods
are presented in Table 3.
’ DISCUSSION
CECT detected one patient with chromophobe RCC and
12 patients with oncocytoma, but CEUS detected oncocy-
toma in 13 patients. The results of histopathology revealed that
the CECT results were correct; chromophobe RCC was found
in one patient, and oncocytoma was found in 12 patients.
These results were consistent with the results of a previous
prospective study (21). Chromophobe RCC is a sharp lesion
with lobes, resembles oncocytoma, and has contrast enhance-
ment that is similar to that of oncocytomas (4), which was why
sonographers considered oncocytoma for a RCC and observed
oncocytomas in 13 patient images, while histopathologists
had observed only 12 oncocytoma slides. This is due to the
incorrect interpretation of the CEUS expert.
When diagnosing clear cell RCC, CEUS, CECT, and
histopathology (n=104) had equal efficiency and accuracy.
These results were consistent with the results of previous
prospective studies (21,22) and retrospective studies (23).
This might be because clear cell RCC is the most common
and well-studied type of kidney lesion.
CEUS found 35 cases of papillary RCC cases, while
histopathology found 32 (and 3 as angiomyolipoma (Fig-
ure 9)). CECT was also performed for contradictory angio-
myolipoma samples (n=3) because there was an unclear
increase in attenuation between unenhanced and enhanced
Figure 5 - Flow diagram of the study.
Table 2 - Anthropological, demographic, and clinical
characteristics of the enrolled patients.
Characteristics Value
Data of the patients included in the study 191
Age (years) Minimum 50
Maximum 69
Mean ± SD 63.51±12.25
Sex Male 137 (72)
Female 54 (28)
Ethnicity Han Chinese 173 (91)
Mongolian 16 (8)
Tibetan 2 (1)
Habit Smokers 120 (63)
Never smoked any kind
of tobacco product
71 (37)
*Serum creatinine (mg/dL) Male 1.9±0.05
Female 1.8±0.06
Body mass index (kg/m2) 25.12±1.89
Comorbidities Diabetes 25 (13)
Hypertension 65 (34)
Hyperlipidemia 76 (40)
Cardiovascular disease 22 (12)
Constant parameters are presented as frequencies (percentages), and
continuous parameters are presented as the mean ± SD.
*Normal value: 0.6–1.1 mg/dL in females and 0.7–1.3 mg/dL in males.
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CT (24), which suggested that the three contradictory samp-
les were actually papillary RCC. Pathologists diagnosed these
three cases as benign tumors with an angiomyolipoma
subtype because all three cases consisted of varying amounts
of smooth muscle cells, mature fat and thick-walled vessels.
Additionally, abnormal vessels were often hyalinized and
thick with eccentric lumen, and smooth muscle cells appeared
to originate and ‘‘radiate’’ off the vessels. The reduced
Figure 6 - Contrast-enhanced ultrasound images of the kidney. A: Clear cell renal carcinoma. B: Papillary renal cell carcinoma-type I. C:
Papillary renal cell carcinoma-type II. D: Infiltrative urothelial renal cell carcinoma. E: Collecting duct renal cell carcinoma. F:
Angiomyolipoma. G: Oncocytoma.
Figure 7 - Contrast-enhanced computed tomography of the kidney. A: Clear cell renal carcinoma. B: Papillary renal cell carcinoma-type
I. C: Papillary renal cell carcinoma-type II. D: Chromophobe renal cell carcinoma. E: Collecting duct renal cell carcinoma. F: Infiltrative
urothelial renal cell carcinoma, G: Angiomyolipoma. H: Oncocytoma.
Figure 8 - Histopathological examinations. A: Clear cell renal carcinoma (lipid-rich cytoplasm with sharply visible nuclei), B: Papillary
renal cell carcinoma-type I (spindle-shaped basophilic cells with scarce cytoplasm), C: Papillary renal cell carcinoma-type II (spindle-
shaped organized cells covered with granular eosinophils with distinct nuclei), D: Chromophobe renal cell carcinoma (large cells with
pale surroundings and perinuclear halos), E: Collecting duct renal cell carcinoma (irregular channels were lined by high-grade cuboidal
to hobnail cells with eosinophilic cytoplasm). F: Infiltrative urothelial renal cell carcinoma (sessile, polypoid, fungating, ulcerated, and
infiltrative lesion with the neoplastic cells separated by a desmoplastic stroma). G: Oncocytoma (nested architecture with a central scar
and bland cytology).
Table 3 - Tumors and their subtypes examined by the diagnostic methods.
Types of tumor Histopathology
Imaging modalities
Untargeted contrast-enhanced
ultrasound
Contrast-enhanced
computed tomography
Data of the patients included in the study 191 191 *p-value 191 *p-value
Total lesions
Malignant lesions 148 (77) 151 (79) 0.804 151 (77) 0.804
Benign lesions 43 (23) 40 (21) 40 (23)
Renal cell carcinoma
Clear cell renal carcinoma 104 (54) 104 (54) 0.991 104 (54) 0.991
Papillary renal cell carcinoma Type-I 12 (7) 15 (9) 15 (9)
Type-II 20 (10) 20 (10) 20 (10)
Collecting duct renal cell carcinoma 6 (3) 6 (3) 6 (3)
Infiltrative urothelial renal cell carcinoma 6 (3) 6 (3) 6 (3)
Non-renal cell carcinoma
Angiomyolipoma 30 (16) 27 (14) 0.58 27 (14) 0.976
Oncocytoma 12 (6) 13 (7) 12 (6)
Chromophobe renal cell carcinoma 1 (1) 0 (0) 1 (1)
Parameters are presented as frequencies (percentages).
The chi-square independence test was used for statistical analysis.
A p value o0.05 was considered significant.
*With respect to histopathological data.
The Bosniak criteria were used to characterize lesions.
Ultrasonographers, radiologists, and pathologists (all had a minimum of 5 years of experience) were involved in analyzing the diagnosis parameters.
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efficiency of various histopathology steps, i.e., toned tissue,
inconsistent staining, and incorrect interpretation, may lead to
misdiagnosis. In precursor lesions, pathological changes have
not yet fully developed, and histological assessments are
subject to diagnostic uncertainty (8). CEUS may be more
efficient in determining the subtype of the malignant tumor to
assist in administering the correct treatment/surgery for RCC,
and it is important to be aware of the limitations of histo-
pathological examinations in the diagnosis of RCC.
However, for collecting duct RCC and infiltrative urothe-
lial RCC, the results were self-explanatory and consistent for
both CEUS and CECT examinations. The histology results
were also similar and suggested that CEUS was equally sen-
sitive, accurate and efficient as the CECT method in detecting
RCC, but the Chinese guidelines on the management of RCC
(15) and USFDA (the United States of Food and Drug
Administration) (18) do not include CEUS for the diagnosis
of RCC; however, CEUS is more accurate in differentiating
between benign and malignant tumors (6). The study sug-
gested that CEUS has the potential to replace CECT for the
diagnosis of RCC.
A total of 27 cases of angiomyolipoma were reported via
CEUS and CECT each. In contrast, histopathology detected
30 cases. Twelve cases of oncocytomas were reported via
histopathology and CECT each, but CEUS reported 13 cases.
These results were consistent with the results of other pro-
spective studies (21,22). One case of chromophobe RCC was
detected through histopathology and CECT each, but CEUS
failed to detect chromophobe RCC. The differentiation of
non-RCC from RCC is problematic for CEUS (25). CEUS and
CECT have substantially different probabilities of detecting
non-RCC (26). Further research is required for the diagnosis
of non-RCC.
The study reported that CEUS had a higher sensitivity but
lower specificity than CECT. The results of the study were
in line with the results of a pilot study (18). This abnormal
parenchymal enhancement on CEUS is required to overcome
issue of specificity.
No adverse effects occurred within the scope of the study.
Levovists has no nephrotoxicity issues because it is secreted
out after the destruction of the microbubbles. Levovists does
not make use of iodine; thus, it does not affect or disrupt the
function of the thyroid gland. Levovists is foreign to the
body, and the immune system can initiate a hypersensitivity
reaction (10). Hypersensitivity reactions were reported in
0.002% of the cases in previous abdominal studies (27). The
incidence of hypersensitivity reactions observed with Levo-
vists is much lower than that observed with iohexol (28).
Patients with elevated serum creatinine were included in this
study and underwent CECT with iohexol. The safety of
patients during the diagnosis of renal lesions with iodinated
contrast agents must be considered.
There were several limitations in this study that need
to be reported, including the retrospective nature, lack of
prospective analysis and chance of bias. The comorbidities
also affect the development of kidney lesions, but this study
did not perform comorbidity analyses. Intra- and inter-
observer agreement is required for ultrasound examinations.
Levovists has a shorter half-life than iohexol and is des-
troyed during scanning, making continuous scanning impos-
sible. Second generation contrast agents (e.g., SonoVue,
Optison, Sonazoid, and Definity) include some inert gases
other than air and have made continuous scanning possible
(29).
’ CONCLUSIONS
Contrast-enhanced ultrasound possesses no nephrotoxi-
city and may not affect thyroid gland function. The use of
first-generation contrast agents, i.e., Levovists, in this study
was safe and made continuous scanning possible for a short
interval of time. This study has helped reach the conclusion
that contrast-enhanced ultrasound might be safe and as
accurate as histopathology. Additionally, these results depict
a very powerful tool with an excellent safety profile that pro-
vides additional information to contrast-enhanced computed
tomography and histopathology for diagnosing kidney
lesions, especially renal cell carcinoma.
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